HRP20240703T1 - Telmisartan za profilaksu ili liječenje hipertenzije kod mačaka - Google Patents
Telmisartan za profilaksu ili liječenje hipertenzije kod mačaka Download PDFInfo
- Publication number
- HRP20240703T1 HRP20240703T1 HRP20240703TT HRP20240703T HRP20240703T1 HR P20240703 T1 HRP20240703 T1 HR P20240703T1 HR P20240703T T HRP20240703T T HR P20240703TT HR P20240703 T HRP20240703 T HR P20240703T HR P20240703 T1 HRP20240703 T1 HR P20240703T1
- Authority
- HR
- Croatia
- Prior art keywords
- telmisartan
- treatment
- pharmaceutically acceptable
- acceptable salt
- hypertension
- Prior art date
Links
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 title claims 46
- 241000282326 Felis catus Species 0.000 title claims 25
- 239000005537 C09CA07 - Telmisartan Substances 0.000 title claims 23
- 229960005187 telmisartan Drugs 0.000 title claims 23
- 238000011282 treatment Methods 0.000 title claims 23
- 206010020772 Hypertension Diseases 0.000 title claims 18
- 238000011321 prophylaxis Methods 0.000 title claims 17
- 150000003839 salts Chemical class 0.000 claims 22
- 238000000034 method Methods 0.000 claims 17
- 230000035488 systolic blood pressure Effects 0.000 claims 9
- 230000037396 body weight Effects 0.000 claims 4
- 230000007423 decrease Effects 0.000 claims 2
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
Claims (15)
1. Telmisartan ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka koje trebaju takvu profilaksu ili liječenje, pri čemu postupak obuhvaća davanje terapijski učinkovite količine telmisartana ili njegove farmaceutski prihvatljive soli mački, dok se terapijski učinkovita količina telmisartana ili njegove farmaceutski prihvatljive soli daje u količini dnevnog doziranja, koja se razlikuje tijekom razdoblja liječenja, gdje količina dnevnog doziranja telmisartana ili njegove farmaceutski prihvatljive soli u prvom vremenskom periodu tijekom razdoblja liječenja iznosi 1,0 do 5,0 mg/kg tjelesne mase, i gdje se količina dnevnog doziranja telmisartana ili njegove farmaceutski prihvatljive soli smanjuje u drugom vremenskom periodu koji se nastavlja na prvi vremenski period tijekom razdoblja liječenja.
2. Telmisartan ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 1, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka, pri čemu je hipertenzija povezana s kroničnom bolesti bubrega ili hipertiroidizmom.
3. Telmisartan ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 1, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka, pri čemu hipertenzija je idiopatska hipertenzija.
4. Telmisartan ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka, pri čemu količina dnevnog doziranja varira na temelju vrijednosti sistoličkog krvnog tlaka (SBP) koji je izmjeren kod mačke.
5. Telmisartan ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka, pri čemu se količina dnevnog doziranja sartana smanjuje za drugi vremenski period s dodavajućom količinom koja se nalazi u rasponu od 0,10 do 0,50 mg/kg tjelesne mase.
6. Telmisartan ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka, pri čemu se količina dnevnog doziranja sartana smanjuje kada se vrijednost sistoličkog krvnog tlaka (SBP) izmjerenog kod mačke, smanjuje za najmanje 10 mmHg ili najmanje 20 mmHg ili za 10 do 150 mmHg, 10 do 100 mmHg, 10 do 80 mmHg, 10 do 50 mmHg, 10 do 30 mmHg, 10 do 20 mmHg, 20 do 150 mmHg, 20 do 100 mmHg, 20 do 80 mmHg, 20 do 50 mmHg, ili 20 do 30 mmHg u odnosu početnu vrijednost SBP koja je izmjerena kod mačke prije prvog vremenskog perioda.
7. Telmisartan ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka, pri čemu se količina dnevnog doziranja sartana smanjuje kada se vrijednost sistoličkog krvnog tlaka (SBP) izmjerenog kod mačke, smanjuje od početne vrijednosti SBP koja je izmjerena kod mačke prije prvog vremenskog perioda na graničnu vrijednost ili ispod nje.
8. Telmisartan ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 7, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka, pri čemu granična vrijednost iznosi 160 ili 170 mmHg.
9. Telmisartan ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka, pri čemu se količina dnevnog doziranja sartana u drugom vremenskom periodu povećava ili smanjuje za treći vremenski period nakon drugog vremenskog perioda, a na temelju promjene u SBP kod mačke koji se mjeri na kraju drugog vremenskog perioda.
10. Telmisartan ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka, pri čemu količina dnevnog doziranja sartana u prvom vremenskom periodu tijekom razdoblja liječenja iznosi 2,0 do 3,0 mg/kg tjelesne mase, i količina dnevnog doziranja sartana u drugom vremenskom periodu iznosi 0,125 do 2,0 mg/kg tjelesne mase.
11. Telmisartan ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka, pri čemu prvi vremenski period traje najmanje 14 dana, ili najmanje 28 dana, ili najmanje 120 dana.
12. Telmisartan ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka, pri čemu dnevna primjena je oralna primjena.
13. Telmisartan ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka, pri čemu se dnevna primjena terapijski učinkovite količine u najmanje jednom dijelu od razdoblja liječenja, provodi u jednostrukoj dozi.
14. Telmisartan ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka, pri čemu se dnevna primjena terapijski učinkovite količine u najmanje jednom dijelu od razdoblja liječenja, provodi u većem broju doza.
15. Telmisartan ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da je za uporabu u postupku za profilaksu ili liječenje hipertenzije kod mačaka, pri čemu postupak isključuje davanje terapijski učinkovite količine telmisartana ili njegove farmaceutski prihvatljive soli mački koja je u dobi od manje od 9 mjeseci ili pri čemu se telmisartan ili njegova farmaceutski prihvatljiva sol daje mački koja je u dobi od najmanje 9 mjeseci ili pri čemu se telmisartan ili njegova farmaceutski prihvatljiva sol daje mački koja je u dobi od 9 mjeseci ili je starija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529587P | 2017-07-07 | 2017-07-07 | |
| EP18740153.4A EP3648761B1 (en) | 2017-07-07 | 2018-07-05 | Telmisartan for the prophylaxis or treatment of hypertension in cats |
| PCT/EP2018/068189 WO2019008077A1 (en) | 2017-07-07 | 2018-07-05 | ANTAGONIST OF THE ANGIOTENSIN II RECEPTOR FOR THE PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240703T1 true HRP20240703T1 (hr) | 2024-08-16 |
Family
ID=62904440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240703TT HRP20240703T1 (hr) | 2017-07-07 | 2018-07-05 | Telmisartan za profilaksu ili liječenje hipertenzije kod mačaka |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10905676B2 (hr) |
| EP (2) | EP3648761B1 (hr) |
| JP (2) | JP7050893B2 (hr) |
| KR (3) | KR20250007040A (hr) |
| CN (1) | CN110785168A (hr) |
| AR (1) | AR112265A1 (hr) |
| AU (1) | AU2018295387B2 (hr) |
| BR (1) | BR112020000194A2 (hr) |
| CA (1) | CA3067918A1 (hr) |
| DK (1) | DK3648761T3 (hr) |
| EA (1) | EA202090205A1 (hr) |
| ES (1) | ES2979279T3 (hr) |
| FI (1) | FI3648761T3 (hr) |
| HR (1) | HRP20240703T1 (hr) |
| HU (1) | HUE067255T2 (hr) |
| LT (1) | LT3648761T (hr) |
| NZ (1) | NZ759782A (hr) |
| PL (1) | PL3648761T3 (hr) |
| PT (1) | PT3648761T (hr) |
| RS (1) | RS65570B1 (hr) |
| SI (1) | SI3648761T1 (hr) |
| WO (1) | WO2019008077A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022540074A (ja) | 2019-07-09 | 2022-09-14 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | イヌの慢性腎臓病の治療のためのテルミサルタン |
| BR112022000398A2 (pt) | 2019-07-09 | 2022-03-03 | Boehringer Ingelheim Vetmedica Gmbh | Telmisartana para o tratamento da hipertensão em cães |
| US20250195525A1 (en) | 2023-12-15 | 2025-06-19 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5671074A (en) | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
| CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| US4880804A (en) | 1988-01-07 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking benzimidazoles |
| US5015651A (en) | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
| CA1338238C (en) | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
| IE70593B1 (en) | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
| DE122010000024I1 (de) | 1990-02-19 | 2010-07-08 | Novartis Ag | Acylverbindungen |
| TW201738B (hr) | 1990-03-20 | 1993-03-11 | Sanofi Co | |
| US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| IL99246A0 (en) | 1990-09-10 | 1992-07-15 | Abbott Lab | Angiotensin ii receptor antagonists and pharmaceutical compositions containing them |
| GB9027210D0 (en) | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| US6028091A (en) | 1990-12-14 | 2000-02-22 | Smithkline Beecham Plc | Medicament |
| SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| US5196537A (en) | 1991-03-21 | 1993-03-23 | G. D. Searle & Co. | 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
| GB9110636D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
| EP0636027B1 (en) | 1992-04-13 | 1999-07-07 | Zeneca Limited | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
| CA2186606A1 (en) | 1994-03-29 | 1995-10-05 | Edward B. Nelson | Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles |
| DE19901921C2 (de) | 1999-01-19 | 2001-01-04 | Boehringer Ingelheim Pharma | Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels |
| US6358986B1 (en) | 1999-01-19 | 2002-03-19 | Boehringer Ingelheim Pharma Kg | Polymorphs of telmisartan |
| DE10018401A1 (de) | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| CA2445913A1 (en) | 2001-05-14 | 2003-10-29 | Merck & Co., Inc. | Method of treatment |
| DE10153737A1 (de) | 2001-10-31 | 2003-05-28 | Boehringer Ingelheim Pharma | Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
| US8980870B2 (en) | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US20070026026A1 (en) | 2005-08-01 | 2007-02-01 | David Delmarre | Oral liquid losartan compositions |
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| CA2653011A1 (en) * | 2008-12-03 | 2010-06-03 | Apotex Technologies Inc | Method and apparatus for packaging and dispensing pharmaceuticals |
| DK2432452T3 (en) * | 2009-05-20 | 2016-10-10 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutically telmisartan drink solution |
| EP3307069B1 (en) * | 2015-06-10 | 2021-08-04 | Hackensack University Medical Center | Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases |
| MX381130B (es) | 2016-09-07 | 2025-03-12 | Saniona As | Composiciones de tesofensina. |
-
2018
- 2018-07-05 EP EP18740153.4A patent/EP3648761B1/en active Active
- 2018-07-05 HR HRP20240703TT patent/HRP20240703T1/hr unknown
- 2018-07-05 AU AU2018295387A patent/AU2018295387B2/en active Active
- 2018-07-05 DK DK18740153.4T patent/DK3648761T3/da active
- 2018-07-05 SI SI201831100T patent/SI3648761T1/sl unknown
- 2018-07-05 CA CA3067918A patent/CA3067918A1/en active Pending
- 2018-07-05 RS RS20240617A patent/RS65570B1/sr unknown
- 2018-07-05 JP JP2020500145A patent/JP7050893B2/ja active Active
- 2018-07-05 FI FIEP18740153.4T patent/FI3648761T3/fi active
- 2018-07-05 EA EA202090205A patent/EA202090205A1/ru unknown
- 2018-07-05 ES ES18740153T patent/ES2979279T3/es active Active
- 2018-07-05 NZ NZ759782A patent/NZ759782A/en unknown
- 2018-07-05 EP EP23204038.6A patent/EP4299120A3/en active Pending
- 2018-07-05 KR KR1020247042412A patent/KR20250007040A/ko active Pending
- 2018-07-05 LT LTEPPCT/EP2018/068189T patent/LT3648761T/lt unknown
- 2018-07-05 WO PCT/EP2018/068189 patent/WO2019008077A1/en not_active Application Discontinuation
- 2018-07-05 BR BR112020000194-5A patent/BR112020000194A2/pt active Search and Examination
- 2018-07-05 AR ARP180101883 patent/AR112265A1/es unknown
- 2018-07-05 CN CN201880033892.1A patent/CN110785168A/zh active Pending
- 2018-07-05 HU HUE18740153A patent/HUE067255T2/hu unknown
- 2018-07-05 US US16/027,422 patent/US10905676B2/en active Active
- 2018-07-05 PT PT187401534T patent/PT3648761T/pt unknown
- 2018-07-05 PL PL18740153.4T patent/PL3648761T3/pl unknown
- 2018-07-05 KR KR1020207003639A patent/KR20200026975A/ko not_active Ceased
- 2018-07-05 KR KR1020237039620A patent/KR20230161541A/ko active Pending
-
2020
- 2020-12-22 US US17/131,312 patent/US20210106564A1/en active Pending
-
2022
- 2022-02-18 JP JP2022023799A patent/JP7402907B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3648761T3 (pl) | 2024-07-22 |
| EP4299120A3 (en) | 2024-03-06 |
| RS65570B1 (sr) | 2024-06-28 |
| KR20250007040A (ko) | 2025-01-13 |
| EP3648761A1 (en) | 2020-05-13 |
| AU2018295387A1 (en) | 2020-01-02 |
| LT3648761T (lt) | 2024-06-10 |
| SI3648761T1 (sl) | 2024-07-31 |
| CN110785168A (zh) | 2020-02-11 |
| EA202090205A1 (ru) | 2020-06-02 |
| NZ759782A (en) | 2023-06-30 |
| AR112265A1 (es) | 2019-10-09 |
| JP7402907B2 (ja) | 2023-12-21 |
| US20210106564A1 (en) | 2021-04-15 |
| PT3648761T (pt) | 2024-06-05 |
| TW201919703A (zh) | 2019-06-01 |
| DK3648761T3 (da) | 2024-06-24 |
| EP4299120A2 (en) | 2024-01-03 |
| KR20200026975A (ko) | 2020-03-11 |
| JP2022075670A (ja) | 2022-05-18 |
| US10905676B2 (en) | 2021-02-02 |
| HUE067255T2 (hu) | 2024-10-28 |
| KR20230161541A (ko) | 2023-11-27 |
| ES2979279T3 (es) | 2024-09-25 |
| EP3648761B1 (en) | 2024-03-13 |
| AU2018295387B2 (en) | 2024-02-15 |
| CA3067918A1 (en) | 2019-01-10 |
| US20190008831A1 (en) | 2019-01-10 |
| WO2019008077A1 (en) | 2019-01-10 |
| JP2020526516A (ja) | 2020-08-31 |
| JP7050893B2 (ja) | 2022-04-08 |
| FI3648761T3 (fi) | 2024-05-21 |
| BR112020000194A2 (pt) | 2020-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240703T1 (hr) | Telmisartan za profilaksu ili liječenje hipertenzije kod mačaka | |
| JP2019514858A5 (hr) | ||
| RU2019134558A (ru) | Композиции и способы лечения анемии | |
| JP2018510178A5 (hr) | ||
| IL316408A (en) | A safe and effective method for treating psoriasis with a specific anti-IL23 antibody | |
| JP2020500152A5 (hr) | ||
| JP2020502261A5 (hr) | ||
| JP2017533972A5 (hr) | ||
| NO20081863L (no) | Forhindring og behandling av gastrointestinal og blaerelidelse assosiert med kemoterapi eller stralingsterapi ved bruk av aktiv vitamin D forbindelse | |
| HRP20230935T1 (hr) | Postupci za liječenje i profilaksu hiv-a i aids-a | |
| MX390667B (es) | Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. | |
| JP2018500546A5 (hr) | ||
| HRP20221185T1 (hr) | Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom | |
| JP2016505050A5 (hr) | ||
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| US10052281B2 (en) | Local administration-type pharmaceutical for improving dysphagia | |
| JP2018505901A (ja) | 統合失調症の治療のためのイロペリドン | |
| HRP20201233T1 (hr) | Spoj izveden od pirazolina i njegova primjena u tjednom doznom režimu protiv upale i bola porijeklom od degenerativnog oboljenja zgloba kod sisavaca | |
| CN105362280A (zh) | 氯硝柳胺磷酸酯用于制备抑制肾脏组织纤维化的药物的用途 | |
| JP2017531042A5 (hr) | ||
| US9974768B2 (en) | Pharmaceutical for improving dysphagia | |
| HK1223549A1 (zh) | 一种阿尔法-亚型选择性磷脂醯肌醇3激酶抑制剂的剂量疗方 | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| TH2201000080A (th) | การรวมกันของไอบูโพรเฟนและทรามาดอลสำหรับการบรรเทาอาการปวด | |
| HRP20230677T1 (hr) | Kombinacija ibuprofena i tramadola za ublažavanje boli |